ENTITY
Venus MedTech

Venus MedTech (2500 HK)

109
Analysis
Health CareChina
Venus MedTech (HangZhou) Inc. develops and sells cardiovascular devices. The Company offers products including aorta, compression loading and conveying systems, and pulmonary artery. Venus MedTech (HangZhou) markets its products throughout China.
more
Refresh
26 Jan 2021 17:18

MicroPort CardioFlow IPO: Valuation Insights

MicroPort aims to raise total net proceeds of $290 million at the mid-point of the IPO price range of HK$11.10-12.20 per share. Overall, we think...

Logo
356 Views
Share
25 Jan 2021 09:52

China Healthcare Weekly (Jan.22)

The article analyzed the new official document for the volume-based purchase,industry viewpoints on China cryogenic storage market and “AI +...

Logo
204 Views
Share
24 Jan 2021 10:20

MicroPort Cardioflow (微创心通) Pre-IPO: Thoughts on Valuation

We are taking a close look at the Microport Cardioflow’s valuation. We are of the view that the company’s fair value should be around USD 3.0 billion.

Logo
405 Views
Share
bullishVenus MedTech
21 Jan 2021 18:57

Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick

Venus MedTech (2500 HK) is looking to raise up to US$187m in its primary placement. At the same time, Peijia Medical (9996 HK) is looking to raise...

Share
20 Jan 2021 01:22

MicroPort CardioFlow IPO Initiation: To Save a Life

MicroPort is pre-marketing for an HK IPO to raise $300 million. With a large addressable market opportunity and VitaFlow’s potentially best-in...

Logo
849 Views
Share
x